Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alyssum Therapeutics

Request full access

Pioneering B cell immunotherapy to regulate immune response and treat complex diseases

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Alyssum Therapeutics

Alyssum Therapeutics is at the forefront of cancer immunology, focusing on pioneering B cell immunotherapy to regulate immune responses and treat complex diseases. The company operates in the biopharmaceutical sector, targeting complex diseases with a particular emphasis on cancer. Alyssum's business model revolves around developing next-generation targeted immunotherapies, with a strong focus on advancing patient outcomes and quality of life. The company generates revenue through the development and potential commercialization of its therapeutic candidates, such as AT 1965, which is currently under clinical trials. Alyssum serves patients with complex diseases, particularly those with hard-to-treat tumors, and actively recruits participants for its clinical trials. The team at Alyssum boasts extensive experience, having been involved with over 20 drugs on the market and multiple recent accelerated USFDA approvals. The company leverages its expertise to push the boundaries of science, aiming to transform patient lives through innovative treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
51.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Immunotherapy, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2025 $2M $73M FemHealth Ventures ↗
SERIES A✓Equity / VC Oct 2024 $15M $58M Accel · Navam Capital · Famy Care Ltd ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Alyssum Therapeutics website traffic

Latest recorded traffic for Alyssum Therapeutics is 2K monthly website visits, up 217.5% over the last three months. Alyssum Therapeutics's team grew 33.3% over the past year.

Latest monthly visits2K 3-month web change+217.5% 1-year team growth+33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alyssum Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Alyssum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Accel
  • Navam Capital
  • Famy Care Ltd
  • FemHealth Ventures
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alyssum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alyssum Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.